Loading organizations...
Renasant Bio develops oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD). Its pipeline includes corrector and potentiator therapies. These treatments restore polycystin protein function, directly addressing genetic and protein dysfunctions. The approach aims to halt disease progression by stabilizing protein folding and enhancing ion channel activity across mutations.
Renasant Bio launched in November 2025, established by founding investor 5AM Ventures. The company originated from the insight that existing ADPKD treatments inadequately address fundamental biological mechanisms. CEO Emily Conley, Ph.D., and CSO Gus Gustafson, Ph.D., bring deep expertise in ADPKD research and drug development to its scientific strategy.
Renasant Bio serves patients globally with autosomal dominant polycystic kidney disease. The company's vision is to transform ADPKD treatment through disease-modifying therapies. Its mission involves correcting the condition's root causes, aiming to significantly improve health outcomes and quality of life for a broad spectrum of patients.
Renasant Bio has raised $55.0M across 1 funding round.
Renasant Bio has raised $55.0M in total across 1 funding round.
Renasant Bio has raised $55.0M across 1 funding round. Most recently, it raised $55.0M Seed in July 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2025 | $55M Seed | — | 5AM Ventures, Atlas Venture | Announced |
Renasant Bio is a biopharmaceutical company developing oral small molecule therapies—correctors and potentiators—to target the underlying biology of autosomal dominant polycystic kidney disease (ADPKD), the most common genetic cause of end-stage renal failure affecting around 12 million people worldwide, including 300,000 in the US.[1][2][4][5] It serves ADPKD patients by restoring function to mutated polycystin proteins (PC1 and PC2), aiming to halt cyst formation and kidney enlargement, unlike current treatments that only manage symptoms.[2][3][4] The company launched in July 2025 with $54.5 million in seed funding from 5AM Ventures, Atlas Venture, OrbiMed, and Qiming Venture Partners, supporting a preclinical pipeline including a lead corrector candidate for broad mutations and a complementary potentiator.[1][2][4]
Early momentum includes incubation by 5AM Ventures and a focused "all-in" strategy on ADPKD, drawing from cystic fibrosis successes like Vertex's Trikafta.[3][4] Leadership features CEO Emily Conley, PhD, and Chief Scientific Officer Gus Gustafson, backed by a board with experts like Natalie Holles and a Scientific Advisory Board including Nira Dahl.[3][4][6]
Renasant Bio emerged from 5AM Ventures' incubation around a "bold idea" to apply cystic fibrosis-style corrector-potentiator therapies to ADPKD, a complex channelopathy causing massive kidney cysts.[2][3][4] Founded in 2025, it launched publicly on July 14, 2025, with $54.5 million seed funding, marking strong early validation from top VCs.[1][2] CEO Emily Conley leads with a vision to fix cellular defects at the root, emphasizing the disease's heterogeneity and unmet need beyond drugs like Tolvaptan.[3][5]
The team humanizes the mission: Conley highlights patients' struggles, like wearing "I'm not pregnant, I have ADPKD" shirts due to enlarged kidneys weighing up to 30 pounds each.[5] Key hires like Gustafson (ex-Johnson & Johnson, Merck) and advisors like Dahl (veteran of major ADPKD trials) bring deep polycystic disease expertise, while the board—majority women—includes Natalie Holles (ex-Third Harmonic Bio CEO).[3][4][6] This assembly reflects pivotal focus on precision assays for protein trafficking and electrophysiology.[2]
Renasant rides the kidney disease biotech wave, where investors eye genetic renal disorders amid rising end-stage failure cases, competing with Novartis, Regulus, and Vertex but differentiating via root-cause correction.[4][5] Timing aligns with CF therapeutic breakthroughs proving channelopathy modulation works, now adapting to ADPKD's 12 million global patients—a massive, underserved market with no true disease modifiers.[2][4][5] Favorable forces include advancing genetic testing (e.g., Metera) for patient stratification and preclinical tools accelerating pipelines.[3]
By focusing exclusively on ADPKD, Renasant influences the ecosystem through expertise-sharing via its SAB and potential to redefine renal medicine, much like Vertex transformed CF—potentially enabling combo therapies and inspiring related channelopathies.[3][4]
Renasant Bio's preclinical corrector (standalone potential) and potentiator combo could reach clinical trials in the next few years, targeting first disease-modifying ADPKD approval amid growing VC interest in nephrology.[4] Trends like AI-driven discovery, genetic diagnostics, and combo regimens will shape its path, with competition from Vertex accelerating validation.[4][5] Influence may evolve from stealth pioneer to ecosystem leader, partnering on trials or expanding to polycystic liver disease if successful—ultimately offering hope to transform "ballooning" kidneys from fate to fixable.[2][5] This seed-funded launch positions Renasant to lead the next era of precision renal therapies.
Renasant Bio has raised $55.0M in total across 1 funding round.
Renasant Bio's investors include 5AM Ventures, Atlas Venture.
